Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2018

View Archived Issues

First patient treated in phase I study of anti-CD47 monoclonal antibody SRF-231

Eli Lilly discovers novel PDE1 inhibitors

Novel serine protease HTRA1 inhibitors identified at Roche

Genentech and Roche present new HsNIK inhibitors

Technical University of Denmark presents ROS-activated methotrexate and aminopterin prodrugs

GlaxoSmithKline divulges novel bromodomain and extra-terminal protein inhibitors

DHX34 expression predicts poor survival in melanoma patients

SAR-191801, an orally active inhibitor of H-PGDS for asthma and COPD

Cosmo Pharmaceuticals submits NDA to the FDA or rifamycin SV MMX

First patient dosed in phase II psoriasis trial of ABY-035

Eiger BioPharmaceuticals receives FDA guidance for lornafarnib HDV development

Biodesix to collaborate with Checkmate Pharmaceuticals on treatment biomarkers

Researchers discover novel phyllanthusmin analog PHY-34

FDA grants fast track designation to Pedmark

Inhaled JAK1 inhibitors synthesized for treating asthma

Helix BioPharma and ProMab Biotechnologies to collaborate on CAR-T therapy

Swedish Orphan Biovitrum launches Ravicti in Europe

Boston Scientific to acquire NxThera

AOBiome Therapeutics' ammonia oxidizing bacteria product well tolerated in phase I study

New gene fusions detected in pleomorphic adenoma

Merus and Vall d'Hebron Institute of Oncology expand collaboration

Deinove enters option and license agreement for Redx's anti-infective program

Innate Biologics to develop recombinant protein platform with the Wistar Institute

Novartis signs licensing agreement for Harvard's biomaterial-based cancer immunotherapies

LSZ-102, a potent SERD showing good oral bioavailability and clinical safety

Bayer's acquisition of Monsanto gets conditional approval in Europe

Allysta initiates phase I/II study of H-1337 for elevated intraocular pressure

Bristol-Myers Squibb studies BMS-986258 alone and with nivolumab in advanced solid tumors

GlaxoSmithKline initiates first-in-human study of GSK-3358699

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...